Last reviewed · How we verify
Zemplar
At a glance
| Generic name | Zemplar |
|---|---|
| Also known as | ABT-358, paricalcitol, Zemplar |
| Sponsor | Danderyd Hospital |
| Target | Vitamin D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Approved indications
- Hyperparathyroidism Secondary to Chronic Renal Failure
Common side effects
- Nausea
- Vomiting
- Edema
Serious adverse events
- Cardiac arrest
- Cerebrovascular accident
- Intestinal ischemia
- Pulmonary edema
- Hypercalcemia
- Adynamic Bone Disease
- Angioedema
- Rectal hemorrhage
- Syncope
- Glaucoma
Key clinical trials
- Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer (PHASE2)
- A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) (PHASE3)
- Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis (EARLY_PHASE1)
- Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer (PHASE1)
- Pre-operative Treatment for Patients With Untreated Pancreatic Cancer (PHASE2)
- PHL Treatment in Pancreatic Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |